v3.26.1
Schedule of Deferred Tax Assets (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Income Tax Disclosure [Abstract]    
Net operating loss carryforwards $ 10,753,257 $ 9,997,830
Stock-based compensation 612,808 604,164
Accrued expenses 379,270 208,283
Deferred research and development expenses 1,268,013 939,744
Deferred tax assets 13,013,348 11,750,021
Valuation allowance (13,013,348) (11,750,021)
Deferred tax assets, net